Safety of dabigatran or rivaroxaban for thoracoscopic ablation in patients with atrial fibrillation

Int J Cardiol. 2015:186:213-5. doi: 10.1016/j.ijcard.2015.03.229. Epub 2015 Mar 18.

Authors

Sung Il Im¹, Dong Seop Jeong², Seung-Jung Park², Kyoung-Min Park², June Huh², June Soo Kim², Young Keun On³

Affiliations

¹ Division of Cardiology, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea.
² Cardiology, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
³ Cardiology, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: yk.on@samsung.com.

PMID: 25828118
DOI: 10.1016/j.ijcard.2015.03.229

No abstract available

Keywords: Atrial fibrillation; New oral anticoagulants; Thoracoscopic ablation.

Publication types

Letter

MeSH terms

Administration, Oral
Antithrombins / administration & dosage
Atrial Fibrillation / complications
Atrial Fibrillation / surgery*
Catheter Ablation / methods*
Dabigatran / administration & dosage*
Factor Xa Inhibitors / administration & dosage
Female
Follow-Up Studies
Humans
Male
Middle Aged
Retrospective Studies
Rivaroxaban / administration & dosage*
Thoracoscopy*
Thromboembolism / etiology
Thromboembolism / prevention & control*
Treatment Outcome

Substances

Antithrombins
Factor Xa Inhibitors
Rivaroxaban
Dabigatran